Clinical Trials on Oropharyngeal Gram-negative Bacilli Colonization

Total 1846 results

GlaxoSmithKline

Completed

Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612

Infections, Meningococcal

Denmark
Novartis Vaccines

Completed

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

Meningococcal Disease

United States, Poland
GlaxoSmithKline

Completed

Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs

Infections, Meningococcal

Lebanon
GlaxoSmithKline

Completed

Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs

Infections, Meningococcal
GlaxoSmithKline

Completed

Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years

Infections, Meningococcal

Belgium
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Meningococcal Disease

Italy
Jiangsu Province Centers for Disease Control and...
Lanzhou Institute of Biological Products Co., Ltd

Completed

Immunogenicity and Safety of Subunit Plague Vaccine

Plague

China
Novartis Vaccines

Completed

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Meningococcal Disease

Austria, Finland, Germany, Italy, Czech Republic
Leiden University Medical Center

Completed

Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines

Meningococcal Disease

Netherlands
EuBiologics Co.,Ltd
Instituto Universitario IVI

Completed

To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men (OCV)

Prevention Harmful Effects

Korea, Republic of
Centers for Disease Control and Prevention
MRC/UVRI and LSHTM Uganda Research Unit; Ministry of Health, Uganda

Unknown

A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans

Plague

Uganda
University Hospital, Clermont-Ferrand
Université d'Auvergne

Terminated

Lcr35 / ICU / P. Aeruginosa

Pseudomonas Infections
Poitiers University Hospital

Recruiting

Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease (CARACIIM)

Meningococcal Infections

France
Assiut University

Not yet recruiting

Frequency of h.Pylori in Children With Dyspeptic Symptoms

H.Pylori Infection
Sunnybrook Health Sciences Centre
Canadian Institutes of Health Research (CIHR)

Recruiting

BALANCE+ Vanguard Phase (BALANCE+)

Gram-negative Bacteremia

Canada
GlaxoSmithKline

Active, not recruiting

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Infections, Meningococcal

United States, Australia, Finland, Poland, Belgium, Brazil, Sweden, Turkey
Jiangsu Province Centers for Disease Control and...

Active, not recruiting

Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization Regimens

Plague

China
Johns Hopkins Bloomberg School of Public Health

Completed

Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine

Cholera | Vibrio Cholerae Infection

Zambia
GlaxoSmithKline

Completed

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

Infections, Meningococcal

Finland
Pfizer

Completed

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION

Finland, Poland
Accelerate Diagnostics, Inc.

Withdrawn

Clinical Impact of Fast Phenotypic Antimicrobial Susceptibility Testing on Patients With Gram-Negative Rod Bacteremia

Gram-negative Bacteremia
Pfizer

Completed

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

Meningococcal Infection

United States, Finland, Czechia, Sweden, Denmark, Germany
GlaxoSmithKline

Completed

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Meningococcal Disease

United States
GlaxoSmithKline

Completed

Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine

Infections, Meningococcal

Philippines, Saudi Arabia
GlaxoSmithKline

Completed

Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years

Infections, Meningococcal

Philippines
GlaxoSmithKline

Completed

Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612

Infections, Meningococcal

Sweden, Denmark
Centre Hospitalier Universitaire de Besancon

Completed

Epidemiology of ST131 in Besançon University Hospital (coliST131)

Escherichia Coli Infections

France
GlaxoSmithKline

Completed

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612

Infections, Meningococcal

Philippines, India
National Institute of Allergy and Infectious Diseases...

Terminated

Enteroaggregative E.Coli (EAEC)

Escherichia Coli Infections

United States
GlaxoSmithKline

Completed

Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine

Infections, Meningococcal

Germany, Austria
GlaxoSmithKline

Completed

Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs

Infections, Meningococcal

Belgium
National Institute of Allergy and Infectious Diseases...

Completed

Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers

Plague

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers

Meningococcal Disease

Italy
Novartis Vaccines

Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Meningococcal Disease

Finland, Czech Republic
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Meningococcal Disease

United Kingdom
GlaxoSmithKline

Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

Infections, Meningococcal

United States
Novartis Vaccines
Novartis

Completed

Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

Meningococcal Disease

Canada, United Kingdom
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

Meningococcal Disease

United Kingdom
London School of Hygiene and Tropical Medicine
Bill and Melinda Gates Foundation

Withdrawn

A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger (VES)

Meningococcal Disease

Mali, Niger
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

Meningococcal Infection

Germany
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.

Gram-Negative Bacterial Infections | Gram-Positive Bacterial Infections | Meningitis | Neurosurgery | Ventriculitis | Intracranial Infections
The University of Hong Kong

Not yet recruiting

Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae (FMT)

Fecal Microbiota Transplantation | Carbapenem-Resistant Enterobacteriaceae Infection
University Hospital Center of Martinique
Centre Hospitalier Universitaire de la Réunion; Centre Hospitalier de Cayenne; University Hospital of Guadeloupe and other collaborators

Recruiting

Comparing Two Antibiotic Therapy Periods (3 Versus 7 Days) in Patients With Mild Leptospirosis and Seen at the Hospital in 5 French Overseas Departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte) (LEPTO3)

Mild Leptospirosis

Martinique, French Guiana, Guadeloupe, Mayotte, Réunion
Groupe Hospitalier de la Rochelle Ré Aunis

Completed

Epidemiology Non-cholera Vibrio Infections (INFECTIVE)

Vibrio Infections

France
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Meningococcal Infections

Czechia, Finland, Italy, Poland, Romania, Spain
U.S. Army Medical Research and Development Command

Enrolling by invitation

Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine

Tularemia

United States
University of Sao Paulo General Hospital
Instituto de Infectologia Emílio Ribas

Completed

Correlation Between Cytokines and the Severity of Meningococcal Disease

Meningococcemia

Brazil
Gamaleya Research Institute of Epidemiology and...

Recruiting

The Surveillance Clinical Study of Rickettsiosis

Rickettsiosis

Russian Federation
U.S. Army Medical Research and Development Command
US Army Medical Research Institute of Infectious Diseases

Withdrawn

FY15-14: Tularemia Vaccine Protocol (NDBR Lot 4) (NDBR)

Tularemia

United States
Walvax Biotechnology Co., Ltd.

Completed

Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.

Meningococcal Infections

China

3

Subscribe